Patents by Inventor William Farr
William Farr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11978545Abstract: Techniques for tracking a progression of a therapeutic procedure that is performed by a patient are disclosed. A notification is received from a server computer system. This notification relates to a tracking process designed to monitor a progress of the patient in performing the therapeutic procedure. After receipt of the notification, a UI is displayed. This UI has a particular visual layout that is designed to facilitate the tracking process. In response to a particular field being selected within the UI, a secret key that de-identifies the patient is accessed. The accessed secret key and a specific image are then encrypted. As a consequence, encrypted data is generated. The encrypted data is then transmitted to the server computer system.Type: GrantFiled: February 8, 2022Date of Patent: May 7, 2024Assignee: ATADAS, INC.Inventors: William Farr, Scot Joseph Penrod
-
Patent number: 11873266Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: July 26, 2021Date of Patent: January 16, 2024Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H Hall, Walter F. Boron
-
Publication number: 20230366051Abstract: A method and an apparatus method for producing direct reduced iron (DRI) from iron ore using biomass as a source of reductant and as a heating source of the iron ore and electromagnetic energy as a further heating source in a furnace having multiple zones. The zones include a preheat zone and a reduction zone between an inlet for briquettes of iron ore and biomass and an outlet for direct reduced iron. The method includes counter-current movement of (a) briquettes of iron ore and biomass in a direction from the inlet to the outlet and (b) combustible gases in an opposite direction in the furnace.Type: ApplicationFiled: November 24, 2021Publication date: November 16, 2023Applicant: Technological Resources Pty. LimitedInventors: Iain William Farr, Rodney James Dry, Michael Buckley
-
Patent number: 11801254Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: November 16, 2020Date of Patent: October 31, 2023Assignee: Aeromics, Inc.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Publication number: 20230332258Abstract: A method for producing direct reduced iron (“DRI”) from iron ore and biomass is disclosed. The method includes heating a batch of iron ore and biomass in each oven chamber of a non-recovery batch oven by a combination (i) the thermal mass of a lining of the oven chamber and (ii) combustion of a fuel gas from at least one other oven chamber and at least partially reducing the iron ore and forming DRI. The method also includes discharging gases from the oven chamber through passageways in a wall and a floor of the oven chamber and further combusting combustible gases and transferring heat to the wall and the floor of the oven chamber as the gases move through the passageways. The method also includes discharging at least a portion of gases from the oven chamber, without passing the gases through passageways in the floor of the oven chamber, and using these gases as a fuel gas in subsequent combustion heating in other batch oven chambers when a first predetermined trigger point is reached.Type: ApplicationFiled: September 20, 2021Publication date: October 19, 2023Inventors: Rodney James Dry, Iain William Farr
-
Publication number: 20220254469Abstract: Techniques for tracking a progression of a therapeutic procedure that is performed by a patient are disclosed. A notification is received from a server computer system. This notification relates to a tracking process designed to monitor a progress of the patient in performing the therapeutic procedure. After receipt of the notification, a UI is displayed. This UI has a particular visual layout that is designed to facilitate the tracking process. In response to a particular field being selected within the UI, a secret key that de-identifies the patient is accessed. The accessed secret key and a specific image are then encrypted. As a consequence, encrypted data is generated. The encrypted data is then transmitted to the server computer system.Type: ApplicationFiled: February 8, 2022Publication date: August 11, 2022Inventors: William FARR, Scot Joseph PENROD
-
Publication number: 20220143048Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: June 16, 2021Publication date: May 12, 2022Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20220081391Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: July 26, 2021Publication date: March 17, 2022Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11238968Abstract: A system can provide efficiency in monitoring prescription medication can include a client computer system configured to service a user interface (UI) for facilitating a pill counting procedure. The client receives a notification from a server computer system to initiate a pill count. The instructions can also cause the system to display a UI on the client computer system to facilitate the pill counting procedure. The displayed layout includes: (i) a timestamp field; (ii) a pill count field; (iii) an image field displaying an image of the pills the user has; (iv) a certification field; and (v) a submit field. On submission, the system can generate an encrypted data file comprising a secret key that de-identifies the user, the image of the pills, and metadata describing conditions associated with the pill count. The system can then transmit the encrypted data file to the server computer system.Type: GrantFiled: July 14, 2021Date of Patent: February 1, 2022Assignee: ATADAS, INC.Inventors: William Farr, Scot Joseph Penrod
-
Publication number: 20210275549Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: November 16, 2020Publication date: September 9, 2021Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Patent number: 11084778Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 17, 2018Date of Patent: August 10, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11071744Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 28, 2019Date of Patent: July 27, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Patent number: 10894055Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: GrantFiled: December 31, 2018Date of Patent: January 19, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr
-
Publication number: 20200297740Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 28, 2019Publication date: September 24, 2020Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
-
Publication number: 20190307779Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.Type: ApplicationFiled: December 31, 2018Publication date: October 10, 2019Applicant: Aeromics, Inc.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
-
Patent number: 10258636Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: GrantFiled: October 24, 2017Date of Patent: April 16, 2019Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Robert Zamboni, John Colucci, Helmi Zaghdane
-
Publication number: 20180334424Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: May 17, 2018Publication date: November 22, 2018Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK, Christopher H. HALL, Walter F. BORON
-
Publication number: 20180169118Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.Type: ApplicationFiled: October 24, 2017Publication date: June 21, 2018Applicant: AEROMICS, INC.Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR, Robert ZAMBONI, John COLUCCI, Helmi ZAGHDANE
-
Patent number: 9994514Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 8, 2013Date of Patent: June 12, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 9949991Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.Type: GrantFiled: November 6, 2014Date of Patent: April 24, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Steven Williams